Neuroprotective effects of raloxifene on experimental spinal cord injury in rats

American Journal of the Medical Sciences

Volumn 345, Issue 1, 2013, Pages 39-44

  Ismailoglu, Ozgur ^a   Oral, Baha ^a   Sütcü, Recep ^b   Kara, Yusuf ^a   Tomruk, Onder ^a   Demir, Necdet ^c  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

Author keywords

IL 1b; Raloxifene; Spinal cord injury; TNF a; Ultrastructure

Indexed keywords

INTERLEUKIN 1BETA; RALOXIFENE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MECHANISM; ELECTRON MICROSCOPY; LAMINECTOMY; MALE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; RAT; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; SPINAL CORD INJURY;

EID: 84871942349     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182522651     Document Type: Article

References (23)

1. Conti A, Cardali S, Genovese T, et al. Role of inflammation in the secondary injury following experimental spinal cord trauma. J Neurosurg Sci 2003;47:89-94.
2. Genovese T, Mazzon E, Crisafulli C, et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther 2006;316:1006-16.
3. Wang CX, Olschowka JA, Wrathall Jr. Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res 1997;759:190-6.
4. Popovich PG, Jones TB. Manipulating neuroinflammatory reactions in the injured spinal cord: back to basics. Trends Pharmacol Sci 2003;24:13-7.
5. Bartholdi D, Schwab ME. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci 1997;9:1422-38.
6. Hayashi M, Ueyama T, Nemoto K, et al. Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury. J Neurotrauma 2000;17:203-18.
7. Sayer FT, Kronvall E, Nilsson OG. Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. Spine J 2006;6:335-43.
8. Ritz MF, Hausmann ON. Effect of 17beta-estradiol on functional outcome, release of cytokines, astrocyte reactivity and inflammatory spreading after spinal cord injury in male rats. Brain Res 2008;1203:177-88.
9. Callier S, Morissette M, Grandbois M, et al. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001;41:131-8.
10. Biewenga E, Cabell L, Audesirk T. Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress. Neurosci Lett 2005; 373:179-83.
11. Frei K, Lins H, Schwerdel C, et al. Antigen presentation in the central nervous system. The inhibitory effect of IL-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. J Immunol 1994;152:2720-8.
12. Harrington JF, Messier AA, Levine A, et al. Shedding of tumor necrosis factor type 1 receptor after experimental spinal cord injury. J Neurotrauma 2005;22:919-28.
13. Kaptanoglu E, Caner HH, Sürücü HS, et al. Effect of mexiletine on lipid peroxidation and early ultrastructural findings in experimental spinal cord injury. J Neurosurg 1999;91(suppl 2):200-4.
14. Ildan F, Polat S, Oner A, et al. Effects of naloxone on sodium- and potassium-activated and magnesium-dependent adenosine-5'-triphosphatase activity and lipid peroxidation and early ultrastructural findings after experimental spinal cord injury. Neurosurgery 1995;36: 797-805.
15. Bagriyanik HA, Ozogul C, Alaygut E, et al. Neuroprotective effects of ketorolac tromethamine after spinal cord injury in rats: an ultrastructural study. Adv Ther 2008;25:152-8.
16. Anthes DL, Theriault E, Tator CH. Characterization of axonal ultrastructural pathology following experimental spinal cord compression injury. Brain Res 1995;702:1-16.
17. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
18. Ismailoglu O, Oral B, Görgülü A, et al. Neuroprotective effects of tamoxifen on experimental spinal cord injury in rats. J Clin Neurosci 2010;17:1306-10.
19. Sontag A, Wan X, Krege JH. Benefits and risks of raloxifene by vertebral fracture status. Curr Meds Res Opin 2010;26:71-6.
20. O'Neill K, Chen S, Brinton RD. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004; 185:63-80.
21. Lei DL, Long JM, Hengemihle J, et al. Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice. Neuroscience 2003;121:659-66.
22. Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004; 89:6097-9.
23. Yang L, Jones NR, Blumbergs PC, et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J Clin Neurosci 2005;12:276-84.